Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$26.27
-1.5%
$22.85
$13.06
$31.77
$3.33B1.511.72 million shs1.66 million shs
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$79.90
-2.6%
$74.86
$14.30
$84.55
$11.55B1.281.54 million shs1.39 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$23.21
-2.9%
$23.01
$13.23
$27.72
$11.94B1.695.97 million shs4.64 million shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$14.28
+2.7%
$13.38
$12.19
$15.71
$11.61B0.271.56 million shs4.15 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-1.46%+2.34%+25.93%+15.52%+82.43%
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-2.56%+4.38%+6.60%+31.48%+415.15%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-2.93%-4.21%+6.62%-8.79%+73.73%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
+2.63%+7.33%+5.03%+2.92%-6.73%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$26.27
-1.5%
$22.85
$13.06
$31.77
$3.33B1.511.72 million shs1.66 million shs
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$79.90
-2.6%
$74.86
$14.30
$84.55
$11.55B1.281.54 million shs1.39 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$23.21
-2.9%
$23.01
$13.23
$27.72
$11.94B1.695.97 million shs4.64 million shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$14.28
+2.7%
$13.38
$12.19
$15.71
$11.61B0.271.56 million shs4.15 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-1.46%+2.34%+25.93%+15.52%+82.43%
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-2.56%+4.38%+6.60%+31.48%+415.15%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-2.93%-4.21%+6.62%-8.79%+73.73%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
+2.63%+7.33%+5.03%+2.92%-6.73%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2.50
Moderate Buy$34.0029.43% Upside
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2.69
Moderate Buy$86.368.09% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.79
Moderate Buy$28.5522.99% Upside
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
1.67
ReduceN/AN/A

Current Analyst Ratings Breakdown

Latest ARQT, ELAN, RDY, and ARWR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetBuy$31.00 ➝ $32.00
6/17/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Boost Price TargetMarket Perform$61.00 ➝ $72.00
6/11/2026
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
DowngradeHold (C+)Hold (C)
5/29/2026
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
UpgradeHold (C)Hold (C+)
5/20/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
DowngradeHold (C-)Sell (D-)
5/13/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Boost Price TargetMarket Perform$35.00 ➝ $46.00
5/12/2026
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
DowngradeHold (C+)Hold (C)
5/11/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
DowngradeSell (D+)Sell (D)
5/8/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Boost Price TargetOutperform$80.00 ➝ $87.00
5/7/2026
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Reiterated RatingBuy$36.00
5/7/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetBuy$30.00 ➝ $31.00
(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$376.07M8.74N/AN/A$1.55 per share16.95
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$829.45M13.57$0.12 per share686.77$3.64 per share21.95
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.46$2.25 per share10.30$13.18 per share1.76
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$335.93B0.04$0.87 per share16.42$4.86 per share2.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$16.14M-$0.03N/A27.36N/A-0.57%-1.41%-0.59%8/5/2026 (Estimated)
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$1.63M-$2.15N/AN/AN/A-48.38%-55.09%-18.13%8/6/2026 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.50N/A19.021.57-4.95%7.42%3.66%8/6/2026 (Estimated)
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$456M$0.5824.6221.971.9112.90%12.34%8.24%7/22/2026 (Estimated)

Latest ARQT, ELAN, RDY, and ARWR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/22/2026Q1 26/27
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.1003N/AN/AN/A$830.50 millionN/A
5/12/2026Q4 25/26
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.09$0.06-$0.03-$0.03$886.58 million$852.55 million
5/7/2026Q2 2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$1.0950-$0.93+$0.1650-$0.93$73.84 million$73.74 million
5/6/2026Q1 2026
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$0.02-$0.09-$0.07-$0.09$103.68 million$105.40 million
5/6/2026Q1 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.34$0.40+$0.06$0.11$1.28 billion$1.37 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/AN/AN/AN/AN/A
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.060.42%+6.96%10.34%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
0.54
2.68
2.46
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
1.41
6.23
6.23
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.60
2.16
1.12
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
0.03
1.80
1.34
CompanyEmployeesShares OutstandingFree FloatOptionable
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
150125.08 million113.33 millionOptionable
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
400140.86 million135.79 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.45 million493.76 millionOptionable
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
27,527834.65 million817.96 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arcutis Biotherapeutics stock logo

Arcutis Biotherapeutics NASDAQ:ARQT

$26.27 -0.39 (-1.46%)
Closing price 06/23/2026 04:00 PM Eastern
Extended Trading
$25.65 -0.62 (-2.35%)
As of 06:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arrowhead Pharmaceuticals stock logo

Arrowhead Pharmaceuticals NASDAQ:ARWR

$79.90 -2.10 (-2.56%)
Closing price 06/23/2026 04:00 PM Eastern
Extended Trading
$78.25 -1.65 (-2.07%)
As of 04:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$23.21 -0.69 (-2.89%)
Closing price 06/23/2026 03:58 PM Eastern
Extended Trading
$23.21 0.00 (-0.02%)
As of 05:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Dr. Reddy's Laboratories stock logo

Dr. Reddy's Laboratories NYSE:RDY

$14.28 +0.37 (+2.66%)
Closing price 06/23/2026 03:58 PM Eastern
Extended Trading
$14.32 +0.04 (+0.28%)
As of 05:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.